프로세사 파마슈티컬스(PCSA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.93 (+1.58%), 시가총액 $0.01B, 52주 최저~최고 $0.17 ~ $6.68.
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinot
프로세사 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
프로세사 파마슈티컬스의 현재 주가는 $1.93 (+1.58%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
프로세사 파마슈티컬스의 시가총액은 약 $0.01B입니다.
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's dru